ReviewApoptosis : an international journal on programmed cell death2026
Disulfidptosis in hepatocellular carcinoma: molecular mechanisms, therapeutic potential, and exploratory insights into chronic liver diseases.
Review in Apoptosis : an international journal on programmed cell death, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Disulfidptosis, a newly identified form of programmed cell death (PCD) that was discovered in 2023, occurs specifically in cells with high SLC7A11 expression when glucose is scarce. The underlying mechanism involves NADPH depletion, which triggers severe disulfide stress and ultimately causes the actin cytoskeleton to collapse. In recent years, researchers have increasingly focused on the potential role of disulfidptosis in liver diseases. Current evidence mainly supports its involvement in hepatocellular carcinoma (HCC), with some preliminary data also suggesting connections to liver cirrhosis and metabolic liver disorders. This review critically synthesizes the molecular mechanisms underlying disulfidptosis, explores its possible links to various liver conditions based on the available evidence, and assesses the potential of disulfidptosis-related genes (DRGs) as exploratory tools for diagnosis, prognostic stratification, and exploratory therapeutic prediction. Together, these insights provide a foundation for understanding liver disease pathogenesis and may guide future research efforts, pending rigorous experimental and clinical validation.
Indexed as
Identifiers
42177709What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.